Fig. 1

EZH2 and HO-1 are relevant in some high-risk and very high-risk MDS patients. a Mononuclear cells were extracted from the bone marrow blood of newly diagnosed patients. cDNA and protein were extracted, and EZH2 and HO-1 were detected by real-time PCR. The basic information of the MDS patients is shown in Table 1. b Linear correlation analysis was used to evaluate EZH2 and HO-1 mRNA expression in high-risk and very high-risk MDS patients. R² represents the correlation between the two genes. c In total, 8 MDS patients with the highest HO-1 expression in qPCR results were selected, and the results were validated by Western blotting to detect EZH2 expression. We also used the Quantity one software to analyze gray values. The relevant values are shown in the histogram. d The levels of proteins in the cells were detected by the laser scanning confocal microscopy. DAPI was ued for nuclear staining. Merge refers to the overlap image. e Western blotting was used to detect the correlation genes expression between EZH2 and HO-1 gene expression in high-risk and very high-risk MDS patients and normal donors. f Western blotting was used to detect EZH2 and HO-1 expression in MDS patients and normal donors. We also used Quantity one software to analyze gray values. The relevant values are shown in the histogram. g Western blotting was used to detect EZH2 and HO-1 expression in different groups of MDS patients. The patients were divided into two groups. One group comprised MDS patients with a good prognosis. The other group comprised AML patients who progressed from MDS and were not sensitive to chemotherapy (decitabine). We also used Quantity one software to analyze gray values. The relevant values are shown in the histogram. Scale bars, 20 μm. Western blotting bands were quantified with Quantity One software. Each sample was normalized to related β-actin expression. All the experiments were repeated, *P < 0.05 (statistically significant)